GM traders! Hope you had a nice Memorial Day Weekend. $NVAX gapping up +20% this morning, covid-19 vaccine play, phase 1 clinical trial news. 2 ways to play this: 1. look to short at premarket high and top of resistance area before the daily gap up, anywhere between 58.62 (PM high) and 61.50, target price is premarket low around 53 area. Risk 1: Reward 6 2....
Technical Analysis - Check/wait if one of the supports will not be broken before buying On a daily chart there might be a Bottom Saucer or Rounding Reversal Pattern Fundamental News: Novavax (NASDAQ:NVAX) is a clinical-stage biotechnology company focused on the discovery, development and commercialisation of vaccines and adjuvants. Through its recombinant...
I missed this guy when I jumped on MRNA and INO earlier this week. Just trying to pin this one down a bit, coronavirus stocks are wild and fun :). For FOMO stocks, typical support and resistance horizontal lines aren't as predictive and you should instead look to the Volume Profile. Support should be right around the POC, which is $40. It should slide down to...
IFFFFF the $1.98 - $2.00 support line holds and buying pressure increases, I expect to see a pretty big upward price movement for the day. Remember folks, just ideas!
A good trade to consider is vaccine development companies. Some of the major players are Novavax, Moderna and Giliad. A conservative price target might be 15-25%.
I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is...
Gilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency...
NASDAQ:NVAX is giving us a great swing trade setup. few days to print. VWAP, fast MA, med MA sitting above slow MA for a long time and offering up a beautiful retracement that will bounce off the indicators right before earnings. Go long, and set a stop where VWAP gets crossed down by the fast MA AND the med MA. Should bring a 4:1 profit to risk ratio.
Looks like Novavax is consolidating for a strong move upward. NASDAQ:NVAX
$NVAX is setting up as nice day trade if we get above $18 and the 52 week high of $18.25 a share. We could see $20 a share pretty easy, especially with the news out today. MELBOURNE, Australia, April 16, 2020 /PRNewswire/ -- As part of the urgent global race to develop a vaccine to tackle the Coronavirus COVID-19 outbreak, Nucleus is due to commence Phase 1...
#Novavax hit the weekly 100SMA and stalling and forming double top. It may pull back on next week.
Hi traders, Tom with another recap here. *In my ID trades, I risk 1% of the account per trade and go for 2% (2:1 RRR ). Sometimes I adapt a little bit as you can see in the description.* I switched to video recaps so you can see the charts in greater detail. Let me know if you like it! Four trades today: 1) UPS - LONG @95.04, stopped out at 94.27 for a...
NVAX ramped on the squeeze as crowd psychology and algorithmic logic took hold in the market crash last week. But this company has as much chance of participating in the actual vaccine as my aunt's family chicken soup recipe. We look for the fade.
NVAX is one, of all the COVID-2019 movers, that we think is most likely to end up being a great short down the line. The long-term trajectory speaks of numerous failures to execute in clinical development, and the company is not part of the inside clique with funding to solve the virus vaccine puzzle. But it's up almost 100% since the news first broke last month.
NVAX The "inevitability bell" may be starting to ring on this one. We called it short a few days ago -- and 7% higher. And now we may be seeing this start to play along. If short with us here, stops should be set in place in the $8.75 area to fence off the unbounded squeeze risk.
NVAX coronavirus panic. Currently, several biotech shares rose significantly yesterday. The driving force is a fundamental fear of the coronavirus. NVAX is one of the potential candidates who can isolate and solve the problem. The fair value of NVAX stock is currently around USD 11.5. Technically, the stock price is in the right place. But what about panic? Is...
NVAX possibly start up trend. wait for 123 confirmation. I also watcing this one